Tamoxifen is a GPER agonist that has been used in clinics for more than 50 years as hormonal therapy for breast cancer based on the classical genomic estrogen receptor (ER) signalling pathway, unrelated to GPER. This evidence concerns the gene GPER1 and breast cancer.